Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors
申请人:AstraZeneca AB
公开号:US10669245B2
公开(公告)日:2020-06-02
The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof),
that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
本公开涉及某些(2S)-N-[(1S)-1-氰基-2-苯基乙基]-1,4-氧氮杂环庚烷-2-甲酰胺化合物(包括其药学上可接受的盐)、
抑制二肽基肽酶 1 (DPP1) 活性的 (2S-N-[(1S) -1-氰基-2-苯基乙基]-1,4-氧氮杂环庚烷-2-甲酰胺化合物(包括其药学上可接受的盐)、它们在治疗和/或预防包括呼吸系统疾病(如哮喘和慢性阻塞性肺病 (COPD))在内的临床病症中的用途、它们在治疗中的使用、含有它们的药物组合物以及制备此类化合物的工艺。